Advisory Board Member

Professor Carole Longson

Carole is an expert in Science policy, market access, pricing and reimbursement. She joined NDA n 2020 and is a highly respected life science leader with considerable track record in sciences policy, health technology assessment and market access.  As a top-level advisor she had been instrumental in supporting client projects from both public and private sector.

Key Areas Of Expertise
  • Advising public and private sectors in life science policy at executive level
  • Health technology assessment with extensive experience in building and maintaining successful international multi-stakeholder networks
  • Developing innovative processes for evidence assessment and translating scientific findings into policy advice.
  • Production of national guidance on medicines, medical devices, diagnostics and digital technologies
Before Joining The NDA Advisory Board

Carole has held several senior Executive and non-Executive Board positions at international level and across public and private sectors. She is the vice chair of Medicines Discovery Catapult, an organisation that assists biotech companies, academic institutions and innovators.

From 2018-2020 she was the Chief Scientific Officer of ABPI, the association of the British pharmaceutical industry, where she was the spokesperson for several national committees to influence science policy across a wide range of initiatives.

Carole led the National Institute for Health and Care Excellence (NICE) as founding member and Executive Director from 2000-2018.

She was also President of Health Technology Assessment International and member of EUnetHTA executive board.

Carole is an Honorary Professor of Health Technology Assessment at the University of Manchester, UK.

Professor Carole Longson


Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.